MacroGenics reports 27% response rate for MGC026 in head‑and‑neck cancer Phase 1 trial
MacroGenics announced interim Phase 1 data for its B7‑H3‑targeted ADC MGC026, showing a best overall response rate of 27% (four confirmed and two unconfirmed partial responses) in 22 heavily pretreated squamous cell carcinoma of the head and neck (SCCHN) patients. The study enrolled 85 patients overall, with grade 3 or higher treatment‑related adverse events in 51% of all participants and 48% in the SCCHN cohort, but no treatment‑related discontinuations. The company plans to start a front‑line expansion cohort combining MGC026 with pembrolizumab in early 2027.
Why it matters
The positive early‑stage efficacy and manageable safety profile could advance MGC026 toward later‑stage trials and potentially add a new asset to MacroGenics’ pipeline, influencing future revenue expectations. The planned pembrolizumab combination may broaden the drug’s market opportunity if later trials confirm benefit.
Key facts
- 1Best overall response rate of 27% (four confirmed and two unconfirmed partial responses) was observed in 22 SCCHN patients. stocktitan.net
- 2A total of 85 patients were enrolled across dose‑escalation and dose‑expansion cohorts as of the September 1 2026 data cutoff. investing.com
- 3Grade 3 or higher treatment‑related adverse events occurred in 51% of all patients. investing.com
- 4Grade 3 or higher treatment‑related adverse events occurred in 48% of the SCCHN cohort. investing.com
- 5No treatment‑related adverse events led to discontinuation in the SCCHN cohort. stocktitan.net
- 6MacroGenics plans to initiate a front‑line expansion cohort with pembrolizumab in early 2027. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.